In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|March 8, 2021
Tergus Pharma Appoints New Vice-President of Business Development
Author(s)BioPharm International Editors
Heather N. Sugrue will serve as the company’s vice-president of Business Development.
Advertisement
Tergus Pharma, a US-based contract development and manufacturing organization (CDMO), announced on March 1, 2021 that Heather N. Sugrue will serve as the company’s vice-president of Business Development.
Prior to her new role at Tergus, Sugrue spent three years at Recro as the vice-president of sales and marketing and six years with Patheon Pharmaceuticals as the senior director of business development for the West Coast, Tergus said in a company press release. Before working at Patheon, Sugrue was employed at Ricerca Biosciences where she supported investigational new drug (IND)-enabling services from lead optimization through IND submission.
“Heather will play a critical role in Tergus’ growth in 2021 and beyond,” said Tergus Pharma chairman and CEO, Dr. Vijendra Nalamothu, in the press release. “Her breadth and depth of sales and business development in the CDMO space will be vital to managing and sustaining our commercial manufacturing expansion while we also maintain our leadership role in topical development. Under Heather’s leadership, Tergus will be expanding the sales team to focus on the growing needs of topical manufacturing in prescription brand and generic manufacturing as well as [over-the-counter] drug product manufacturing.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5